Could a cancer drug tame cushing disease?

NCT ID NCT03774446

Recruiting now Disease control Sponsor: Cedars-Sinai Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests seliciclib, an oral drug, in 13 adults with Cushing disease. The goal is to see if 4 weeks of treatment can lower high cortisol levels to normal or reduce them by at least half. Researchers will also monitor safety and check for changes in tumor size and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Seliciclib (R-roscovitine)
What this could lead to: If successful, this could point toward a new oral treatment option for Cushing disease, potentially reducing the need for surgery or long-term medication.
What could go wrong: This is a small, early-phase trial with only 13 participants, so results may not apply broadly. The drug may not effectively lower cortisol or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUSHING DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ACTH-dependent Cushing syndrome Cushing disease due to pituitary adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUSHING DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.